Accepted Manuscript

Switching between ranibizumab and aflibercept for the treatment of neovascular agerelated macular degeneration (nAMD)

Irmela Mantel, Mark C. Gillies, Eric H. Souied

PII: S0039-6257(17)30279-5

DOI: 10.1016/j.survophthal.2018.02.004

Reference: SOP 6784

To appear in: Survey of Ophthalmology

Received Date: 19 October 2017

Revised Date: 9 February 2018

Accepted Date: 15 February 2018

Please cite this article as: Mantel I, Gillies MC, Souied EH, Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration (nAMD), *Survey of Ophthalmology* (2018), doi: 10.1016/j.survophthal.2018.02.004.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration (nAMD)

Irmela Mantel¹, Mark C. Gillies², Eric H. Souied³

¹Department of Ophthalmology, University of Lausanne, Lausanne, Switzerland; ²The Save Sight and Eye Health Institute, Sydney Medical School, The University of Sydney, Sydney NSW, Australia; ³Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, University Paris Est Creteil, Creteil, France

Corresponding author: Dr Irmela Mantel, MD

<u>Address:</u> University Eye Hospital Jules Gonin, 15 Av. de France – Case postale 133, CH – 1000 Lausanne 7, Switzerland

Email: irmela.mantel@fa2.ch

Telephone: +41 21 626 85 89

Fax: +41 21 626 87 30

Download English Version:

https://daneshyari.com/en/article/8795164

Download Persian Version:

https://daneshyari.com/article/8795164

Daneshyari.com